2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
体验更多LetPub AI科研工具 >> | |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 | 新 已发表SCI？是时候来Springer出书了！ |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Blood Cancer Journal BLOOD CANCER J （此期刊被最新的JCR期刊SCIE收录） LetPub评分 8.3
50人评分
我要评分
声誉 9.5 影响力 7.6 速度 7.0 | |||||||||||||||||||||
| 期刊ISSN | 2044-5385 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：13.76 | |||||||||||||||||||||
| 2025-2026自引率 | 3.6%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年IF （数据来源于网友提供） | 13.998数据由网友[desert6638]收集提供 | |||||||||||||||||||||
| h-index | 37 | |||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://www.nature.com/bcj | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | http://mts-bcj.nature.com/cgi-bin/main.plex | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Aberrant glycosylation in hematologic malignancies: mechanisms, immune evasion, and therapeutic targeting Author: Lu, Xiao; Song, Zhouying; Wang, Chunhui; Pan, Bing; Xu, Ziqi; Wang, Zilong; Wang, Hequn; Wang, Xiaobo; Tang, Bo Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01493-z Utility of dual assessment of cyTRBC1 and cyTRBC2 by flow cytometry for identifying clonality in sCD3-negative to dimly expressing T cells Author: Li, Mingyong; Fu, Jun; Li, Yanxin; Fan, Xiaoming; Zhang, Liuyun; Zhou, Lingjie; Zhang, Jin; Zhang, Juan; Xi, Qian Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01483-1 Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study Author: Yang, Fan; Liu, Rui; Fu, Zhonghua; Guo, Yuelu; Ma, Lixia; Cao, Miaomiao; Deng, Biping; Chang, Alex H.; Wu, Haifeng; Gan, Shilin; Chen, Chen; Ke, Xiaoyan; Hu, Kai Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01476-0 Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma Author: Kumar, Shaji; Jagannath, Sundar; Weisel, Katja C.; Rosinol, Laura; Leleu, Xavier; Dimopoulos, Meletios-Athanasios; Kastritis, Efstathios; Siegel, David S.; Monge, Jorge; Du, Juan; de la Rubia, Javier; Asensi Canto, Pedro; Lee, Jae Hoon; Mateos, Maria-Victoria; Puertas, Borja; Gozzetti, Alessandro; Dytfeld, Dominik; Ocio, Enrique M.; Blade, Joan; Ozaki, Shuji; Beksac, Meral; Escalante, Fernando; Nagaraj, Madhu; Hassan, Rafla; Bonar, Nicolle; Spin, Paul; Shokoohi, Mostafa; Siddiqui, Muhaimen; Wang, Di; Hou, Kevin; West, Michael E. D.; Hampp, Christian; Green, Jeannette; Humblet, Olivier; Breskin, Alexander; Harnett, James; Ge, Wenzhen; Sobel, Rachel E.; Jalbert, Jessica J.; Kroog, Glenn S.; Rodriguez Lorenc, Karen; Ma, Qiufei; Durie, Brian G. M Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01466-2 | |||||||||||||||||||||
| 期刊语言要求 | Language Presenting your work in a well-structured manuscript and in well-written English gives it its best chance for editors and reviewers to understand it and evaluate it fairly. Many researchers find that getting some independent support helps them present their results in the best possible light. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Blood Cancer Journal的语言要求，还能让Blood Cancer Journal编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Blood Cancer Journal编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | Yes | |||||||||||||||||||||
OA期刊相关信息 | 文章处理费：需要（ GBP3390; USD4990; EUR3890; ） 文章处理费豁免：查看说明 其他费用：没有 期刊主题关键词：hematologic malignancies、blood cancer、immunology 相关链接：Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||
| 通讯方式 | CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW | |||||||||||||||||||||
| 出版商 | Springer Nature | |||||||||||||||||||||
| 涉及的研究方向 | ONCOLOGY- | |||||||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||
| 出版年份 | 2011 | |||||||||||||||||||||
| 年文章数 | 105点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 100.00% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 92.38% | |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
  | ||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) 中科院的全球OA期刊索引（OAJ） | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2044-5385%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： >12周，或约稿 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 容易 | |||||||||||||||||||||
| 版面费/APC文章处理费信息 | 文章处理费：需要（ GBP3390; USD4990; EUR3890; ） 文章处理费豁免：查看说明 其他费用：没有 LetPub提供文章处理费（APC）支持服务，可以用人民币支付版面费啦！ | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Blood Cancer Journal顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Aberrant glycosylation in hematologic malignancies: mechanisms, immune evasion, and therapeutic targeting Author: Lu, Xiao; Song, Zhouying; Wang, Chunhui; Pan, Bing; Xu, Ziqi; Wang, Zilong; Wang, Hequn; Wang, Xiaobo; Tang, Bo Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01493-z PubMed DOI |
| 2. | Utility of dual assessment of cyTRBC1 and cyTRBC2 by flow cytometry for identifying clonality in sCD3-negative to dimly expressing T cells Author: Li, Mingyong; Fu, Jun; Li, Yanxin; Fan, Xiaoming; Zhang, Liuyun; Zhou, Lingjie; Zhang, Jin; Zhang, Juan; Xi, Qian Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01483-1 PubMed DOI |
| 3. | Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study Author: Yang, Fan; Liu, Rui; Fu, Zhonghua; Guo, Yuelu; Ma, Lixia; Cao, Miaomiao; Deng, Biping; Chang, Alex H.; Wu, Haifeng; Gan, Shilin; Chen, Chen; Ke, Xiaoyan; Hu, Kai Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01476-0 PubMed DOI |
| 4. | Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma Author: Kumar, Shaji; Jagannath, Sundar; Weisel, Katja C.; Rosinol, Laura; Leleu, Xavier; Dimopoulos, Meletios-Athanasios; Kastritis, Efstathios; Siegel, David S.; Monge, Jorge; Du, Juan; de la Rubia, Javier; Asensi Canto, Pedro; Lee, Jae Hoon; Mateos, Maria-Victoria; Puertas, Borja; Gozzetti, Alessandro; Dytfeld, Dominik; Ocio, Enrique M.; Blade, Joan; Ozaki, Shuji; Beksac, Meral; Escalante, Fernando; Nagaraj, Madhu; Hassan, Rafla; Bonar, Nicolle; Spin, Paul; Shokoohi, Mostafa; Siddiqui, Muhaimen; Wang, Di; Hou, Kevin; West, Michael E. D.; Hampp, Christian; Green, Jeannette; Humblet, Olivier; Breskin, Alexander; Harnett, James; Ge, Wenzhen; Sobel, Rachel E.; Jalbert, Jessica J.; Kroog, Glenn S.; Rodriguez Lorenc, Karen; Ma, Qiufei; Durie, Brian G. M Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01466-2 PubMed DOI |
| 5. | Efficacy and safety of short-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia Author: Liu, Ge; Zhou, Yile; Lou, Yinjun; Ai, Hao; Mao, Liping; Wang, Qian; Wu, Hongfei; Tong, Hongyan; Wei, Xudong; Jin, Jie; Wang, Huafeng; Yin, Qingsong Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01460-8 PubMed DOI |
| 6. | Imatinib and nilotinib are equally successful in achieving therapy-free remission Author: Cheng, Fang; Wang, Yu; Yang, Yunfan; Du, Xin; Zhu, Yu; Weng, Jianyu; Xu, Na; Huang, Jian; Liu, Zhenfang; Ren, Hongbo; Zhao, Huifang; Zhu, Huanling; Jiang, Qian; Zhang, Yanli; Li, Weiming Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01462-6 PubMed DOI |
| 7. | Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26) Author: Wei, Juying; Cai, Qingqing; Zhang, Liling; Zou, Liqun; Li, Zengjun; Zhou, Keshu; Wu, Huijing; Qiu, Lihua; Su, Liping; Ding, Kaiyang; Zhou, Hui; Yu, Li; Li, Fei; Li, Wenyu; Lin, Li'e; Xiao, Qing; Wang, Erhua; Jing, Hongmei; Zheng, Meifang; Zhang, Hongyu; Gao, Yuhuan; Gao, Da; Chen, Lijia; Jin, Jie Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01452-8 PubMed DOI |
| 8. | Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma: a retrospective cohort study Author: Zou, Qihua; Cao, Yi; Wang, Liang; Li, Wuping; Yin, Qingsong; Wu, Yudan; Jing, Hongmei; Peng, Zhigang; Sun, Xiuhua; Rao, Jun; Chen, Ying; Zhang, Hongyu; Zeng, Dongfeng; Li, Bingzong; Zhao, Ying; Zhang, Xudong; Zhang, Yuchen; Gao, Yan; Bai, Bing; Xia, Yi; Fang, Yu; Chen, Zouxiang; Nie, Man; Fang, Xiaojie; Bai, Shenrui; Huang, Huiqiang; Cai, Qingqing; Cai, Jun Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01459-1 PubMed DOI |
| 9. | Long-term outcomes of autologous stem cell transplantation for AL amyloidosis: a 15-year experience from a Chinese referral center and a comparison of different eras Author: Liu, Mengnan; Guo, Jinzhou; Chen, Wencui; Wu, Xiaomei; Xu, Weiwei; Huang, Xianghua Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01464-4 PubMed DOI |
| 10. | Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies Author: Li, Tingting; Wang, Chaoyu; Xiao, Qing; Zhang, Xiaomei; Yang, Zailin; Li, Jun; Liu, Yao Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01453-7 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共12条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
